Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | UBE2N | P61088 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209798 | 0.80 | SMN1; SMN2 (0.65) | MAPTRXFP1GAAL3MBTL1LMNA | |
| SCHEMBL24209799 | 0.76 | RXFP1 (0.82) | MAPTRXFP1GAAL3MBTL1LMNA | |
| SCHEMBL10175968 | 0.72 | RECQL (0.75) | MAPTRXFP1GAAL3MBTL1LMNA | |
| SCHEMBL25482064 | 0.72 | LMNA (0.69) | MAPTGAALMNAALDH1A1HPGD | |
| SCHEMBL14426817 | 0.67 | MAPT (0.70) | MAPTGAAL3MBTL1LMNAALDH1A1 | |
| SCHEMBL24029049 | 0.67 | POLB (0.66) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14426815 | 0.67 | MAPT (0.69) | MAPTRXFP1GAAL3MBTL1LMNA | |
| SCHEMBL29354709 | 0.66 | ALDH1A1 (0.76) | MAPTGAALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14426800 | 0.65 | MAPT (0.77) | MAPTRXFP1GAAL3MBTL1LMNA | |
| SCHEMBL25482055 | 0.65 | PNP (0.64) | MAPTGAALMNAALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | MAPT 3296/4885RXFP1 4138/4885GAA 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.